Triple-positive breast cancer involves tumors positive for estrogen, progesterone, and HER2 receptors, affecting treatment decisions and strategies. Diagnosis includes imaging and biopsy to confirm ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A year of trastuzumab emtansine (T‑DM1) can keep about 98% of women with small, early‑stage ...
HER2-positive breast cancer is driven by HER2 protein overexpression, historically linked to poor outcomes but now improved by targeted therapies. Treatment varies by stage, involving surgery, ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results